CN203107746U - Aspirin dipyridamole slow-release structure - Google Patents
Aspirin dipyridamole slow-release structure Download PDFInfo
- Publication number
- CN203107746U CN203107746U CN 201220724911 CN201220724911U CN203107746U CN 203107746 U CN203107746 U CN 203107746U CN 201220724911 CN201220724911 CN 201220724911 CN 201220724911 U CN201220724911 U CN 201220724911U CN 203107746 U CN203107746 U CN 203107746U
- Authority
- CN
- China
- Prior art keywords
- aspirin
- layer
- dipyridamole
- utility
- model
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The utility model relates to an aspirin dipyridamole slow-release structure, which comprises a dipyridamole layer 1, an isolation layer 2, an aspirin layer 3 and a protective layer 4 successively from inside to outside. According to the utility model, as the isolation layer is arranged between the dipyridamole layer and the aspirin layer, the situation that the dipyridamole layer and the aspirin layer contact each other to result in generation of aspirin degradation product salicylic acid can be prevented; and the protective layer is arranged outside the aspirin layer, and can effectively prevent aspirin from interacting with outside moisture, thus reducing aspirin degradation rate.
Description
Technical field
This utility model relates to a kind of pharmaceutical dosage form structure, particularly a kind of aspirin-dipyridomole release structures.
Background technology
Along with the aged tendency of population process is accelerated, the cardiovascular and cerebrovascular disease sickness rate improves rapidly, and antiplatelet aggregation is the important step for the treatment of cardiovascular and cerebrovascular disease.Aspirin (Aspirin is called for short ASP) and dipyridamole (Dipyridamole is called for short DP) are widely used clinically as medicament for resisting platelet aggregation, are mainly used in preventing diseases such as thrombosis, arteriosclerosis and scheming infarction.In recent years, the compound solid preparation of aspirin-dipyridomole existing application clinically.This medicine is antithrombotic choice drug by world health organisation recommendations; Be to be the optimal drug that prevents myocardial infarction by U.S. antiplatelet experimenter association, famous PARISI experimental verification.
Patent CN2798942Y discloses a kind of utility model of aspirin-dipyridomole slow releasing tablet, this utility model is by the aspirin lamella, blank adjuvant sealing coat and three layers of composition of dipyridamole, suppress the last coating of three-layer tablet at three laminate machines, these arts demand three laminate machines, inevitable aspirin contacts with dipyridamole in operating process simultaneously, aspirin easily decomposes the generation free salicylic acid under alkalescence or weak basic condition, dipyridamole is again alkalescent medicine, produce free salicylic acid with accelerating the aspirin decomposition behind the aspirin mixed pressuring plate, be difficult to reach the quality control standard of free salicylic acid in the aspirin.
Summary of the invention
The purpose of this utility model is to provide a kind of novel aspirin-dipyridomole slow releasing pharmaceutical structure, to solve the problem of aspirin degraded in the prior art.
The technical solution of the utility model is: a kind of aspirin-dipyridomole release structures comprises dipyridamole layer 1, sealing coat 2, aspirin layer 3, protective layer 4 from the inside to the outside successively.
Wherein said dipyridamole layer is made up of the dipyridamole extended-release label, and wherein the dipyridamole extended-release label is made by following supplementary material:
Described sealing coat is made up of coating materials, alcoholic solution, and its proportioning is:
Coating materials 1-10 weight portion
Alcoholic solution 10-60 weight portion
Described aspirin layer always mixes granulometric composition by aspirin, and wherein aspirin always mixes granule and made by following supplementary material:
Described protective layer is made up of coating materials, alcoholic solution, and its proportioning is:
Coating materials 4-20 weight portion
Alcoholic solution 50-300 weight portion
Preparation method of the present utility model is:
(1) preparation of dipyridamole extended-release sheet sealing coat coated cores:
Take by weighing dipyridamole, slow-release material, filler by recipe quantity, place wet granulator, adopt alcoholic solution soft material processed, granulate, drying, granulate adds lubricant, mix homogeneously, tabletting; The weightening finish of sealing coat coating is as dipyridamole extended-release sheet sealing coat coated cores;
(2) aspirin always mixes the preparation of granule
With aspirin and L-tartaric acid difference crushing screening, pregelatinized Starch, spray-dried lactose, stearic acid be sieving for standby respectively; Take by weighing aspirin by recipe quantity and mix with L-tartaric acid, add pregelatinized Starch again and mix, take by weighing spray-dried lactose by recipe quantity then and mix, adding microcrystalline Cellulose PH101 again mixes, add stearic acid at last, mix homogeneously always mixes granule as aspirin;
(3) preparation of aspirin-dipyridomole slow release clad sheet
Always mix granule as skin with dipyridamole extended-release sheet sealing coat coated cores as internal layer, aspirin, bag core tablet machine is suppressed double-deck clad sheet;
(4) protective layer coating weightening finish, namely.
This utility model is between dipyridamole and aspirin are two-layer sealing coat to be arranged, and can stop both to be in contact with one another and cause the salicylic generation of aspirin catabolite; When the preparation aspirin always mixes, adopt dried mixing method preparation simultaneously, avoided aspirin and water directly to contact and caused that salicylic acid generates; The outer matcoveredn of this utility model aspirin layer, this protective layer can effectively stop aspirin and the moisture in the external world to interact, and reduce the aspirin degradation speed.
Description of drawings:
Fig. 1 is the generalized section of a kind of aspirin-dipyridomole release structures of this utility model,
Description of reference numerals is as follows:
1-dipyridamole layer, 2-sealing coat, 3-aspirin layer, 4-protective layer.
The specific embodiment
Below in conjunction with the drawings and specific embodiments this utility model is described in detail.
Embodiment 1:
As shown in Figure 1, this utility model aspirin-dipyridomole release structures comprises dipyridamole layer 1, sealing coat 2, aspirin layer 3, protective layer 4 from the inside to the outside successively.
The dipyridamole layer:
Sealing coat:
Opadry 80W 620004Yellow 3kg
20% alcoholic solution 28kg
The aspirin layer:
Protective layer:
Opadry 295K 620010Yellow 8kg
80%7 alcoholic solution 126kg
Take by weighing dipyridamole, hypromellose K4M, lactose by recipe quantity, put successively in the wet granulator, adopt 30% ethanol soft material processed, 18 mesh sieves are granulated, and temperature of charge is no more than 45 ℃ and is dried to LOD≤2.0%, 10 mesh sieve granulate; Add stearic acid, mix homogeneously; Adopt Φ=9.5mm scrobicula drift tabletting; The weightening finish of Opadry 80W 620004Yellow sealing coat coating is to 3%, as dipyridamole extended-release sheet sealing coat coated cores; With aspirin pulverized 30 mesh sieves, L-tartaric acid was pulverized 80 mesh sieves, pregelatinized Starch, spray-dried lactose are crossed 18 mesh sieves respectively, stearic acid is crossed 20 mesh sieves, and be standby; Take by weighing aspirin by recipe quantity and mix with L-tartaric acid, add pregelatinized Starch again and mix, add spray-dried lactose then and mix, add microcrystalline Cellulose PH101 again and mix, add stearic acid at last, mix homogeneously always mixes granule as aspirin; Always mix granule as skin with dipyridamole extended-release sheet sealing coat coated cores as internal layer, aspirin, adopt Φ=double-deck plain sheet of 12mm scrobicula drift compacting bag core; The weightening finish of Opadry 295K 620010Yellow protective layer coating is to 3%, namely.
Claims (3)
1. an aspirin-dipyridomole release structures is characterized in that comprising successively from the inside to the outside dipyridamole layer (1), sealing coat (2), aspirin layer (3), protective layer (4).
2. aspirin-dipyridomole release structures as claimed in claim 1 is characterized in that described dipyridamole layer (1) is made up of the dipyridamole extended-release label.
3. aspirin-dipyridomole release structures as claimed in claim 1 is characterized in that described aspirin layer (3) always mixes granulometric composition by aspirin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201220724911 CN203107746U (en) | 2012-12-26 | 2012-12-26 | Aspirin dipyridamole slow-release structure |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201220724911 CN203107746U (en) | 2012-12-26 | 2012-12-26 | Aspirin dipyridamole slow-release structure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN203107746U true CN203107746U (en) | 2013-08-07 |
Family
ID=48888130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201220724911 Expired - Lifetime CN203107746U (en) | 2012-12-26 | 2012-12-26 | Aspirin dipyridamole slow-release structure |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN203107746U (en) |
-
2012
- 2012-12-26 CN CN 201220724911 patent/CN203107746U/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103006649B (en) | Compound preparation of valsartan amlodipine tablet (I) and preparation method thereof | |
| CN101703513B (en) | Compound sustained-release preparation of aspirin and clopidogrel or pharmaceutically acceptable salt thereof | |
| CN101632647A (en) | Preparation method for compound preparation comprising aspirin and alkaline drugs | |
| CN103908456B (en) | Tenofovir, lamivudine and efavirenz three compound recipe pellet tablet and preparation method thereof | |
| CN101259132B (en) | Aspirin dipyridamole sustained-release capsules and production method | |
| CN203107745U (en) | Aspirin dipyridamole slow-release structure | |
| CN102526748B (en) | Oral tablet containing Valsartan, Hydrochioro and Amlodipine Besylate Tablet | |
| CN203107746U (en) | Aspirin dipyridamole slow-release structure | |
| CN101347413A (en) | Quetiapine sustained release tablets and method of preparing the same | |
| CN111939136A (en) | Compound preparation containing ticagrelor and aspirin and preparation method thereof | |
| CN101693017A (en) | Medicament composition of levetiracetam and preparation process | |
| CN101756916A (en) | Compound vitamin B6 sustained release tablets and preparation process thereof | |
| CN2798942Y (en) | Aspirin dipyridamole sustained-release tablet | |
| CN110237073A (en) | A kind of olmesartan medoxomil amlodipine and preparation method thereof | |
| KR101801064B1 (en) | Three-layered tablet for treating stomach and intestines disease | |
| CN103893192A (en) | Cardiovascular disease treatment sustained-release tablets and preparation method thereof | |
| CZ301299B6 (en) | Solid pharmaceutical composition with atorvastatin and telmisartan active ingredients | |
| CN102552170A (en) | Solid preparation taking prasugrel benzene sulfonate as active component | |
| CN101623282B (en) | Aspirin-dipyridomole sustained-release capsule and preparation method thereof | |
| CN101756923A (en) | Lovastatin and nicotinic acid double-layer sustained release tablets and preparation process | |
| CN101352440A (en) | Guaifenesin, pseudoephedrine hydrochloride and dextromethorphan hydrobromide sustained-release preparation and preparation method thereof | |
| CN101411747B (en) | Salvia root polyphenol acid orally disintegrating tablets and preparation method thereof | |
| CN101249080A (en) | Acetylkitasamycin dispersible tablet and method of preparing the same | |
| RU2303980C2 (en) | Medicinal formulation showing anti-aggregating effect and method for its preparing | |
| CN101537005B (en) | Codein and chlorphenamine compound sustained release capsules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: SHANXI YABAO PHARMACEUTICAL Group Corp. Assignor: YABAO PHARMACEUTICAL Co.,Ltd. BEIJING Contract record no.: 2016990000514 Denomination of utility model: Aspirin dipyridamole slow-release structure Granted publication date: 20130807 License type: Common License Record date: 20161221 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20130807 |